2 weeks Ago By ABMN Staff
Rhumbline Advisers increased its holdings in Compass Therapeutics, Inc. ( NASDAQ:CMPX – Free Report ) by 10.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 131,789 shares of the company’s stock after purchasing an additional 12,315 shares during the quarter. Rhumbline Advisers’ holdings in Compass Therapeutics were worth $132,000 at the end of the most recent quarter. Other large investors have also recently added to or reduced their stakes in the company.
Opaleye Management Inc. acquired a new stake in shares of Compass Therapeutics during the 1st quarter valued at $6,277,000. Pennant Investors LP purchased a new stake in shares of Compass Therapeutics during the fourth quarter valued at $310,000.
CM Management LLC lifted its holdings in shares of Compass Therapeutics by 148.0% during the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after purchasing an additional 185,000 shares during the last quarter.
Pale Fire Capital SE boosted its position in shares of Compass Therapeutics by 301.0% in the 4th quarter. Pale Fire Capital SE now owns 181,055 shares of the company’s stock valued at $282,000 after purchasing an additional 135,900 shares during the period.
Finally, Vanguard Group Inc. increased its stake in Compass Therapeutics by 1.7% in the 1st quarter.
Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after purchasing an additional 71,008 shares in the last quarter. 68.
43% of the stock is currently owned by institutional investors. Compass Therapeutics Trading Up 3.9 % Shares of NASDAQ:CMPX opened at $1.
88 on Monday. The business’s 50 day moving average is $1.33 and its 200-day moving average is $1.
41. The firm has a market capitalization of $258.67 million, a PE ratio of -5.
22 and a beta of 0.88. Compass Therapeutics, Inc.
has a 1-year low of $0.77 and a 1-year high of $2.34.
Wall Street Analyst Weigh In CMPX has been the subject of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, August 7th.
LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Monday, September 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.
00 price objective on shares of Compass Therapeutics in a report on Monday, August 12th. Read Our Latest Stock Report on CMPX Compass Therapeutics Company Profile ( Free Report ) Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Read More Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. ( NASDAQ:CMPX – Free Report ).
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
